Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-826: Pembrolizumab plus chemotherapy vs chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
jRCT2080224122Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Pembrolizumab + chemotherapy ± bevacizumab with Placebo + chemotherapy ± bevacizumab (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2080224122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224122.